Federal contractor · SEATTLE, WA

VIRTICI LLC

No contract obligations recorded for VIRTICI LLC in FY2026. Since FY2018: $1.2M. It also received $2.4M in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
V29SWGG4MQ64
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 585.4KFY2018
  2. 0FY2020
  3. 0FY2021
  4. 599.6KFY2022

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for VIRTICI LLC in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

VIRTICI LLC received $2.4M in federal assistance in FY2026, on 10 actions (4 new awards), +25% vs FY2025. Its largest program was 93.837 · Cardiovascular Diseases Research ($903.6K).

Assistance · FY2026
$2.4M
New awards
4
Actions
10
Since FY2021
$14.4M

Assistance by fiscal year

  1. 2MFY2021
  2. 2.4MFY2022
  3. 2.6MFY2023
  4. 3MFY2024
  5. 1.9MFY2025
  6. 2.4MFY2026

By type

  1. Grants$2.4M100%

Top programs

  1. 93.837 · Cardiovascular Diseases Research$903.6K37%
  2. 93.121 · Oral Diseases and Disorders Research$614.6K25%
  3. 93.855 · Allergy and Infectious Diseases Research$606.7K25%
  4. 93.846 · Arthritis, Musculoskeletal and Skin Diseases Research$306.3K13%

Awarding agencies

  1. National Institutes of Health$2.4M100%
    Department of Health and Human Services

Largest awards

  1. A NOVEL BISPECIFIC ANTIBODY FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS - PROJECT SUMMARY OUR OBJECTIVE IS TO PRODUCE A BISPECIFIC…$3.6M
    93.837 · Cardiovascular Diseases Research· National Institutes of Health· Project grant· Mar 20, 2022 – Jun 1, 2026· R44HL164202
  2. A NOVEL PEPTIDE FOR THE ORAL TREATMENT AND PREVENTION OF P. GINGIVALIS INFECTION - PROJECT SUMMARY OUR GOAL IS TO DEVELOP A FIRST-IN-CLASS…$1.6M
    93.121 · Oral Diseases and Disorders Research· National Institutes of Health· Project grant· Sep 19, 2024 – Aug 4, 2026· R44DE033568
  3. A NOVEL BLOOD TEST FOR EARLY DIAGNOSIS OF FRONTOTEMPORAL LOBAR DEGENERATION - PROJECT SUMMARY OUR OBJECTIVE IS TO DEVELOP A BLOOD-BASED…$700K
    93.866 · Aging Research· National Institutes of Health· Project grant· Aug 15, 2024 – Aug 13, 2026· R43NS139747
  4. A NOVEL ANTI-INFECTIVE THERAPY FOR TREATING PERIODONTITIS - PROJECT SUMMARY OUR GOAL IS TO DEVELOP A FIRST-IN-CLASS INHIBITOR OF P…$617.1K
    93.121 · Oral Diseases and Disorders Research· National Institutes of Health· Project grant· Aug 8, 2025 – Jul 21, 2026· R43DE034614
  5. A NOVEL SUBLINGUAL VACCINE TO PREVENT NEISSERIA GONORRHOEAE INFECTION - PROJECT SUMMARY OUR GOAL IS TO ADVANCE A NOVEL, SAFE AND EFFECTIVE…$613K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Apr 19, 2023 – May 18, 2026· R43AI174574
  6. A NOVEL PREVENTATIVE AND TREATMENT FOR KLEBSIELLA PNEUMONIAE INFECTION - PROJECT SUMMARY OUR GOAL IS TO DEVELOP A FIRST-IN-CLASS, ORALLY…$306.5K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Sep 2, 2026 – Sep 2, 2026· R43AI188659

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 3, 2026, loaded Oct 3, 2026 · FY2021–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 3, 2026, loaded Oct 3, 2026.